ESTA · XBRL financial data

Establishment Labs Holdings financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ESTA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	84,676	126,682	161,700	165,151	166,025	211,076
Cost of revenue	32,174	41,278	55,105	58,174	56,500	64,768
Gross profit	52,502	85,404	106,595	106,977	109,525	146,308
Research and development	13,793	18,315	20,269	26,428	19,706	20,247
Selling, general and administrative	66,625	92,229	125,984	145,575	139,806	165,069
Total operating expenses	80,418	110,544	146,253	172,003	159,512	185,316
Operating income (loss)	(27,916)	(25,140)	(39,658)	(65,026)	(49,987)	(39,008)
Interest income	15	23	87	1,020	1,477	423
Interest expense	9,373	9,062	11,760	15,393	20,829	25,256
Other income (expense)	(2,679)	(6,270)	(3,177)	816	(15,289)	5,819
Income tax expense (benefit)	104	1,427	2,385	(81)	(32)	(6,958)
Net income (loss)	(38,121)	(41,139)	(75,209)	(78,502)	(84,596)	(51,064)
Earnings per share, basic USD per share	(1.63)	(1.72)	(3.08)	(3.07)	(3.00)	(1.72)
Earnings per share, diluted USD per share	(1.63)	(1.72)	(3.08)	(3.07)	(3.00)	(1.72)
Weighted average shares, basic thousands of shares	23,316	23,973	24,458	25,600	28,162	29,620
Weighted average shares, diluted thousands of shares	23,316	23,973	24,458	25,600	28,162	29,620

Fiscal years (ESTA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	84,523	53,415	66,355	40,035	90,347	75,572
Accounts receivable	19,127	24,437	35,423	46,918	65,002	77,497
Inventory	23,210	28,407	36,583	79,471	78,766	85,611
Prepaid and other current assets	5,439	7,012	11,543	8,477	8,922	11,260
Total current assets	132,299	113,271	149,904	174,901	243,037	249,940
Property and equipment, net	16,202	18,658	51,092	77,205	78,028	75,615
Right-of-use asset	2,610	2,206	3,702	3,381	5,561	4,339
Goodwill	465	465	465	465	1,209	1,209
Total assets	156,388	139,529	211,061	268,641	346,831	357,167
Accounts payable	9,722	14,475	20,034	41,624	44,760	43,109
Accrued liabilities	14,532	16,236	17,237	13,690	16,536	18,856
Total current liabilities	25,900	31,889	38,959	57,150	68,278	82,142
Long-term debt	49,832	51,906	175,461	188,739	219,577	247,522
Lease liability, non-current	1,923	1,900	3,200	2,712	4,203	2,820
Total liabilities	81,427	88,790	219,246	250,246	293,736	333,620
Accumulated deficit	(165,246)	(206,385)	(281,594)	(360,096)	(444,692)	(495,756)
Total stockholders' equity	74,961	50,739	(8,185)	18,395	53,095	23,547
Total liabilities and equity	156,388	139,529	211,061	268,641	346,831	357,167
Common shares outstanding (cover page) thousands of shares	23,547	24,125	24,418	27,205	28,846	29,321

Fiscal years (ESTA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(38,121)	(41,139)	(75,209)	(78,502)	(84,596)	(51,064)
Stock-based compensation	—	10,407	13,358	14,362	14,404	11,415
Depreciation and amortization	—	2,500	2,500	2,800	4,700	6,200
Net cash from operating activities	(12,510)	(27,532)	(52,166)	(88,513)	(58,516)	(50,890)
Purchases of property and equipment	2,423	2,425	2,851	7,908	6,114	6,049
Net cash from investing activities	(5,559)	(7,163)	(34,791)	(24,547)	(15,611)	(7,028)
Proceeds from issuing common stock	63,855	0	0	84,538	99,484	0
Net cash from financing activities	64,670	4,052	100,255	86,227	125,895	40,434
Net change in cash	46,868	(31,108)	12,940	(26,320)	50,312	(14,775)

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Establishment Labs Holdings	71,157	67,542	(16,602)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
NovoCure	96,734	193,399	22,667	116.9M	—	Q3 FY26 10-QSep 30, 2026
Heartflow	34,362	64,082	(8,577)*	87.0M	19.0 quarters	Q2 FY26 10-QJun 30, 2026
Integra Lifesciences Holdings	252,261	411,182	95,977*	77.8M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	23,997	not reported	6,348*	48.9M	—	Q2 FY26 10-QJun 30, 2026
SI-BONE	35,311	55,704	5,940*	45.1M	—	Q3 FY26 10-QSep 30, 2026
CONMED	47,972	335,557	49,411*	29.8M	—	Q3 FY26 10-QSep 30, 2026
Embecta	214,700	271,700	41,800*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Alphatec Holdings	79,936	221,172	18,856*	155.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.